Income Statement Balance Sheet Cash Flow Statement
Annual Financials for Adamas Pharmaceuticals Inc.
Fiscal year is January-December. All values USD millions. 2012 2013 5-year trend
Sales/Revenue - - - 37.47M 71.1M
Cost of Goods Sold (COGS) incl. D&A - - - 41,000 66,000
COGS excluding D&A - - - 0 0
Depreciation & Amortization Expense - - - 41,000 66,000
Depreciation - - - 41,000 66,000
Amortization of Intangibles - - - 0 0
Gross Income - - - 37.43M 71.03M
2012 2013 5-year trend
SG&A Expense - - - 17.48M 14.01M
Research & Development - - - 9.19M 7.41M
Other SG&A - - - 8.29M 6.6M
Other Operating Expense - - - 0 0
Unusual Expense - - - 1.33M 4.53M
EBIT after Unusual Expense - - - (1.33M) (4.53M)
Non Operating Income/Expense - - - (207,000) (292,000)
Non-Operating Interest Income - - - - -
Equity in Affiliates (Pretax) - - - 0 0
Interest Expense - - - 376,000 88,000
Gross Interest Expense - - - 376,000 88,000
Interest Capitalized - - - 0 0
Pretax Income - - - 18.04M 52.11M
Income Tax - - - 300,000 1.19M
Income Tax - Current Domestic - - - 303,000 1.19M
Income Tax - Current Foreign - - - (2,000) (1,000)
Income Tax - Deferred Domestic - - - 0 0
Income Tax - Deferred Foreign - - - (1,000) 1,000
Income Tax Credits - - - 0 0
Equity in Affiliates - - - 0 0
Other After Tax Income (Expense) - - - (5.03M) (16.42M)
Consolidated Net Income - - - 12.71M 34.5M
Minority Interest Expense - - - 0 0
Net Income - - - 12.71M 34.5M
Extraordinaries & Discontinued Operations - - - 0 0
Extra Items & Gain/Loss Sale Of Assets - - - 0 0
Cumulative Effect - Accounting Chg - - - 0 0
Discontinued Operations - - - 0 0
Net Income After Extraordinaries - - - 12.71M 34.5M
Preferred Dividends - - - 1.27M 1.44M
Net Income Available to Common - - - 11.44M 33.07M
EPS (Basic) - - - 1.21 4.13
Basic Shares Outstanding - - - 9.49M 13.41M
EPS (Diluted) - - - 1.17 3.51
Diluted Shares Outstanding - - - 9.92M 15.79M
EBITDA - - - 19.99M 57.08M
Copyright 2014 FactSet Research Systems Inc. All rights reserved. Source FactSet Fundamentals.